Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1856–1859. doi: 10.1128/aac.37.9.1856

Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.

J A Hobden 1, J M Hill 1, L S Engel 1, R J O'Callaghan 1
PMCID: PMC188082  PMID: 8239596

Abstract

This study was conducted to determine whether the age of the host influences the pathogenesis and therapeutic outcome of drug-treated Pseudomonas aeruginosa keratitis. Young (3- to 5-month-old) and old (1.5- to 3-year-old) rabbits were intrastromally infected with P. aeruginosa ATCC 27853. Sixteen hours later, rabbits in both age subpopulations were divided into three groups and treated topically as follows: group 1, phosphate-buffered saline; group 2, 0.3% ciprofloxacin; and group 3, 0.3% ciprofloxacin, 1.0% prednisolone, and 0.03% flurbiprofen. Drops were given every 15 min for 1 h and then every 30 min for 9 h. At 27 h postinfection, ocular pathology was graded with a slit lamp examination (SLE) scoring system. Aqueous humor was collected for ciprofloxacin quantitation, and corneas were harvested for bacterial enumeration and estimation of polymorphonuclear leukocytes. Young rabbits had more severe inflammation and pathology than old rabbits. At 27 h postinfection, SLE scores and polymorphonuclear leukocyte numbers were significantly higher for young rabbits than old rabbits (P < 0.02), regardless of treatment. Prednisolone and flurbiprofen significantly reduced SLE scores in both age groups (P < 0.03) without affecting the antimicrobial efficacy of ciprofloxacin.

Full text

PDF
1856

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fox R. A. Atypical presentation of geriatric infections. Geriatrics. 1988 May;43(5):58-9, 63-4, 68. [PubMed] [Google Scholar]
  2. Gray L. D., Kreger A. S. Rabbit corneal damage produced by Pseudomonas aeruginosa infection. Infect Immun. 1975 Aug;12(2):419–432. doi: 10.1128/iai.12.2.419-432.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gritz D. C., Lee T. Y., Kwitko S., McDonnell P. J. Topical anti-inflammatory agents in an animal model of microbial keratitis. Arch Ophthalmol. 1990 Jul;108(7):1001–1005. doi: 10.1001/archopht.1990.01070090103049. [DOI] [PubMed] [Google Scholar]
  4. Hazlett L. D., Kreindler F. B., Berk R. S., Barrett R. Aging alters the phagocytic capability of inflammatory cells induced into cornea. Curr Eye Res. 1990 Feb;9(2):129–138. doi: 10.3109/02713689008995199. [DOI] [PubMed] [Google Scholar]
  5. Hobden J. A., O'Callaghan R. J., Hill J. M., Hagenah M., Insler M. S., Reidy J. J. Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis. Curr Eye Res. 1992 Mar;11(3):259–265. doi: 10.3109/02713689209001777. [DOI] [PubMed] [Google Scholar]
  6. Hobden J. A., Reidy J. J., O'Callaghan R. J., Insler M. S., Hill J. M. Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci. 1990 Oct;31(10):1940–1944. [PubMed] [Google Scholar]
  7. Johnson M. K., Hobden J. A., Hagenah M., O'Callaghan R. J., Hill J. M., Chen S. The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1990 Nov;9(11):1107–1114. doi: 10.3109/02713689008997584. [DOI] [PubMed] [Google Scholar]
  8. Matsumoto K., Shams N. B., Hanninen L. A., Kenyon K. R. Cleavage and activation of corneal matrix metalloproteases by Pseudomonas aeruginosa proteases. Invest Ophthalmol Vis Sci. 1993 May;34(6):1945–1953. [PubMed] [Google Scholar]
  9. Nanda M., Pflugfelder S. C., Holland S. Fulminant pseudomonal keratitis and scleritis in human immunodeficiency virus-infected patients. Arch Ophthalmol. 1991 Apr;109(4):503–505. doi: 10.1001/archopht.1991.01080040071029. [DOI] [PubMed] [Google Scholar]
  10. Ohadi C., Litwin K. L., Moreira H., Kwitko S., Gauderman W. J., Gritz D. C., Gwon A., Jones R., McDonnell P. J. Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis. Cornea. 1992 Sep;11(5):398–403. doi: 10.1097/00003226-199209000-00007. [DOI] [PubMed] [Google Scholar]
  11. Rootman D. S., Hobden J. A., Jantzen J. A., Gonzalez J. R., O'Callaghan R. J., Hill J. M. Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit. Arch Ophthalmol. 1988 Feb;106(2):262–265. doi: 10.1001/archopht.1988.01060130276043. [DOI] [PubMed] [Google Scholar]
  12. Simons R. J., Reynolds H. Y. Altered immune status in the elderly. Semin Respir Infect. 1990 Dec;5(4):251–259. [PubMed] [Google Scholar]
  13. Solana R., Villanueva J. L., Peña J., De la Fuente M. Cell mediated immunity in ageing. Comp Biochem Physiol A Comp Physiol. 1991;99(1-2):1–4. doi: 10.1016/0300-9629(91)90224-z. [DOI] [PubMed] [Google Scholar]
  14. Steuhl K. P., Döring G., Henni A., Thiel H. J., Botzenhart K. Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections. Invest Ophthalmol Vis Sci. 1987 Sep;28(9):1559–1568. [PubMed] [Google Scholar]
  15. Williams R. N., Paterson C. A., Eakins K. E., Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res. 1982;2(7):465–470. doi: 10.3109/02713688208996350. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES